Simultaneous detection of BRCA mutations and large genomic rearrangements in germline DNA and FFPE tumor samples

The development of breast and ovarian cancer is strongly connected to the inactivation of the BRCA1 and BRCA2 genes by different germline and somatic alterations, and their diagnosis has great significance in targeted tumor therapy, since recently approved PARP inhibitors show high efficiency in the...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerzők: Enyedi Márton Zsolt
Jaksa Gábor
Pintér Lajos
Sükösd Farkas
Gyuris Zoltán
Hajdu Adrienn
Keresztné Határvölgyi Erika
Priskin Katalin
Haracska Lajos
Dokumentumtípus: Cikk
Megjelent: 2016
Sorozat:ONCOTARGET 7 No. 38
Tárgyszavak:
doi:10.18632/oncotarget.11259

mtmt:3115596
Online Access:http://publicatio.bibl.u-szeged.hu/26490
LEADER 02385nab a2200313 i 4500
001 publ26490
005 20230214081614.0
008 230214s2016 hu o 0|| Angol d
022 |a 1949-2553 
024 7 |a 10.18632/oncotarget.11259  |2 doi 
024 7 |a 3115596  |2 mtmt 
040 |a SZTE Publicatio Repozitórium  |b hun 
041 |a Angol 
100 1 |a Enyedi Márton Zsolt 
245 1 0 |a Simultaneous detection of BRCA mutations and large genomic rearrangements in germline DNA and FFPE tumor samples  |h [elektronikus dokumentum] /  |c  Enyedi Márton Zsolt 
260 |c 2016 
300 |a 61845-61859 
490 0 |a ONCOTARGET  |v 7 No. 38 
520 3 |a The development of breast and ovarian cancer is strongly connected to the inactivation of the BRCA1 and BRCA2 genes by different germline and somatic alterations, and their diagnosis has great significance in targeted tumor therapy, since recently approved PARP inhibitors show high efficiency in the treatment of BRCA-deficient tumors. This raises the need for new diagnostic methods that are capable of performing an integrative mutation analysis of the BRCA genes not only from germline DNA but also from formalin-fixed and paraffin-embedded (FFPE) tumor samples. Here we describe the development of such a methodology based on next-generation sequencing and a new bioinformatics software for data analysis. The diagnostic method was initially developed on an Illumina MiSeq NGS platform using germline-mutated stem cell lines and then adapted for the Ion Torrent PGM NGS platform as well. We also investigated the usability of NGS coverage data for the detection of copy number variations and exon deletions as a replacement of the conventional MLPA technique. Finally, we tested the developed workflow on FFPE samples from breast and ovarian cancer patients. Our method meets the sensitivity and specificity requirements for the genetic diagnosis of breast and ovarian cancers both from germline and FFPE samples. 
650 4 |a Általános orvostudomány 
700 0 1 |a Jaksa Gábor  |e aut 
700 0 1 |a Pintér Lajos  |e aut 
700 0 1 |a Sükösd Farkas  |e aut 
700 0 1 |a Gyuris Zoltán  |e aut 
700 0 1 |a Hajdu Adrienn  |e aut 
700 0 2 |a Keresztné Határvölgyi Erika  |e aut 
700 0 2 |a Priskin Katalin  |e aut 
700 0 2 |a Haracska Lajos  |e aut 
856 4 0 |u http://publicatio.bibl.u-szeged.hu/26490/1/3115596.pdf  |z Dokumentum-elérés